BioSpace News Archive

The U.S. FDA is expected to give the go-ahead for Pfizer and BioNTech’s COVID-19 vaccine for adolescents ages 12 and older within the week.

Companies across the biotech and biopharma industries recently reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.

Confluent Medical Technologies Inc. announced a strategic investment in The Electrospinning Company Ltd. Electrospinning, a UK-based company, has developed a proprietary electrospinning process which will expand the design options utilized in the structural heart market and fully automate the process of attaching biomedical textiles to heart valve frames..

Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI, announced that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 World Changing Ideas Awards.

Ernesto Aycardi, M.D. joins as Chief Development Officer and Eslie Dennis, MBChB, FCP joins as Chief Medical Officer, North America A new Global Medical Affairs Excellence function will be led by Deborah Braccia, BSN, MPA, PhD.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on April 30, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that it will report its first quarter 2021 financial results and provide a business update on Wednesday, May 12, 2021, after the close of the U.S. financial markets.

Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the three months ended March 31, 2021 and provided a corporate update.

Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the granting of an inducement award to a new employee.

Stryker announced that its Board of Directors has declared a quarterly dividend of $0.63 per share payable July 30, 2021 to shareholders of record at the close of business on June 30, 2021, representing an increase of 9.6% versus the prior year and unchanged from the previous quarter.